Response to induction therapy by assigned treatment
| . | AraC-DNR (N = 107) . | AraC-DNR + CsA (N = 119) . | ||
|---|---|---|---|---|
| No. of patients . | Percent of patients (CI) . | No. of patients . | Percent of patients (CI) . | |
| CR | 35 | 33 (24-42) | 47 | 39 (31-48) |
| RD | 50 | 47 (37-56) | 37 | 31 (23-39) |
| Died during aplasia | 3 | 3 | 3 | 3 |
| Indeterminate* | 16 | 15 | 22 | 18 |
| Not adequately assessed | 3 | 3 | 10 | 8 |
| . | AraC-DNR (N = 107) . | AraC-DNR + CsA (N = 119) . | ||
|---|---|---|---|---|
| No. of patients . | Percent of patients (CI) . | No. of patients . | Percent of patients (CI) . | |
| CR | 35 | 33 (24-42) | 47 | 39 (31-48) |
| RD | 50 | 47 (37-56) | 37 | 31 (23-39) |
| Died during aplasia | 3 | 3 | 3 | 3 |
| Indeterminate* | 16 | 15 | 22 | 18 |
| Not adequately assessed | 3 | 3 | 10 | 8 |
Died within 7 days after completing induction therapy; or died later with (1) no posttreatment marrow examination and (2) no posttreatment peripheral blood smear demonstrating leukemia.